(Q38098098)

28 August 2017

title

Epidermal growth factor receptor as a therapeutic target in glioblastoma (English)

1 reference

28 August 2017

B Kalman

1

1 reference

28 August 2017

E Szep

series ordinal

2

1 reference

28 August 2017

F Garzuly

series ordinal

3

1 reference

28 August 2017

D E Post

series ordinal

4

1 reference

28 August 2017

publication date

11 April 2013

1 reference

28 August 2017

published in

NeuroMolecular Medicine

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

420-434

1 reference

Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Gene therapy for brain tumors: basic developments and clinical implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Targeting ErbB receptors in high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Epidermal growth factor receptor mutation study for 5 years, in a population of patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

A multigene predictor of outcome in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

The MET oncogene is a functional marker of a glioblastoma stem cell subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Emerging insights into the molecular and cellular basis of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Proteomic and immunologic analyses of brain tumor exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

RNA interference therapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

TGF-β2 signaling in high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Epidermal growth factor receptor: a re-emerging target in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

EGFR targeted therapy: view from biological standpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Blockade of EGFR signaling promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27(KIP1) and MMP3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

A simplified approach for the molecular classification of glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

STAT3 as a Therapeutic Target for Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Cooperative Hedgehog-EGFR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Lipomatous supratentorial primitive neuroectodermal tumor with glioblastomatous differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

EGFR mutations and sensitivity to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Cetuximab, its clinical use and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Autocrine, paracrine and juxtacrine signaling by EGFR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

The development of HKI-272 and related compounds for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Antitumor activity of a novel antisense oligonucleotide against Akt1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8229-Y

Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study.

21 January 2018

1 reference

12 December 2020

Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme

1 reference

12 December 2020

Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of the niche

1 reference

12 December 2020

The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches

1 reference

12 December 2020

Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.

1 reference

12 December 2020

Mini-review: bmx kinase inhibitors for cancer therapy.

1 reference

12 December 2020

A novel hybrid peptide targeting EGFR-expressing cancers

1 reference

12 December 2020

Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.

1 reference

12 December 2020

The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization

1 reference

12 December 2020

Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles

1 reference

12 December 2020

Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.

1 reference

12 December 2020

MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.

1 reference

12 December 2020

Current status of immunotherapy and gene therapy for high-grade gliomas

1 reference

12 December 2020

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

1 reference

12 December 2020

RNA interference therapeutics for cancer: challenges and opportunities (review).

1 reference

12 December 2020

Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo

1 reference

12 December 2020

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer

1 reference

12 December 2020

Gli proteins encode context-dependent positive and negative functions: implications for development and disease

1 reference

12 December 2020

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

1 reference

12 December 2020

Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma

1 reference

12 December 2020

10.1007/S12017-013-8229-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1030022927

0 references

1 reference